The Relationship of Phosphatidylinositol 3 Kinase Expression to Grading and Metastasis in Luminal Subtype Breast Cancer Patients

Completed

• Conditions: patients with the luminal subtype breast cancer; metastasis; breast cancer; phosphatidylinositol 3-kinase; luminal subtype

• Registration Number: TCTR20240615001
• Lead Sponsor: Self funding

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-05-01
• Study Start: 2024-06-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 74

Inclusion Criteria

The Inclusion Criteria included female breast cancer patients aged 17 to 65 years with the luminal subtype, a normal BMI, metastatic or non-metastatic disease, and willingness to participate in the study.

Exclusion Criteria

Exclusion criteria included luminal subtype breast cancer patients with positive HER2/Neu immunohistochemistry examinations, the presence of other malignancies (colorectal cancer, liver cancer, lung cancer, brain cancer), or tissue samples not suitable for immunohistochemistry examination (discohesion, denaturation).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PI3K expression After patients underwent surgery immunohistochemistry examination

Secondary Outcome Measures

Name	Time	Method
Characteristic data, histopathological grading and metastasis (presence or absence). When patien admitted to our hospital age, sex, histopathological grading (I, II, or III) and metastasis (presence or absence).